Bayer (BAYN) PT Set at €95.00 by Cfra
Bayer (FRA:BAYN) has been assigned a €95.00 ($110.47) price objective by equities research analysts at Cfra in a research note issued on Thursday. The firm currently has a “buy” rating on the healthcare company’s stock. Cfra’s target price points to a potential upside of 29.27% from the company’s previous close.
Other research analysts also recently issued research reports about the stock. equinet set a €118.00 ($137.21) price target on shares of Bayer and gave the company a “buy” rating in a report on Monday, June 4th. Sanford C. Bernstein set a €120.00 ($139.53) price target on shares of Bayer and gave the company a “buy” rating in a report on Monday, June 4th. Jefferies Financial Group set a €123.00 ($143.02) price target on shares of Bayer and gave the company a “buy” rating in a report on Monday, June 4th. UBS Group set a €130.00 ($151.16) price target on shares of Bayer and gave the company a “buy” rating in a report on Friday, June 1st. Finally, DZ Bank reissued a “buy” rating on shares of Bayer in a research note on Tuesday, June 19th. Nine investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of €104.05 ($120.98).
Shares of FRA:BAYN opened at €73.49 ($85.45) on Thursday. Bayer has a 12 month low of €91.58 ($106.49) and a 12 month high of €123.82 ($143.98).
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Featured Article: Market Capitalization
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.